THE INVESTOR

▶주메뉴 바로가기

▶본문 바로가기

The Korea Herald

MOBILE

Bio

Jan. 19, 2025
Biocom California poised to bridge Korean biotech firms to US opportunities

For Korean investors and companies looking to engage with California’s dynamic life science sector, Biocom California Honorary President Joe Panetta assured that the association offers a wealth of resources to create abundant opportunities for cross-country collaboration and innovation. "We want to find partners and work in hubs that bring opportunity to our members to expand their business and access to capital," Panetta said during a press briefing held Wednesday in San Francisco on the sideli
Jan. 17, 2025
[JPM 2025] Lotte Biologics to provide one-stop ADC services at Syracuse Campus

SAN FRANCISCO ― Lotte Biologics CEO James Park unveiled the firm’s new platform for antibody-drug conjugates, a promising class of anticancer drugs, as its biopharmaceutical production facility in the US is getting ready to welcome its first client. At the JP Morgan Healthcare Conference's Asia-Pacific sessions on Thursday, the pharmaceutical unit of Lotte Group introduced its proprietary and innovative ADC platform, SoluFlex Link, and announced plans to provide one-stop ADC services in collabor
Jan. 17, 2025
[JPM 2025] Chaebol scions in search of next growth drivers at JPM conference

SAN FRANCISCO -- Heirs to Korea’s leading conglomerates stepped onto the global biopharma stage at this year’s JP Morgan Healthcare Conference, highlighting their ambitions in the pharmaceutical and biotech sectors. At the conference held Monday through Thursday in San Francisco, key figures including Seo Jin-seok of Celltrion, Shin Yoo-yeol of Lotte Biologics, and Chey Yoon-chung of SK Biopharmaceuticals, underscored their companies’ commitment to future growth by building connections with part
Jan. 16, 2025
Samsung Biologics powers up ADC business with new facility, key partnerships

SAN FRANCISCO -- Samsung Biologics has made a major move into the antibody-drug conjugate market, announcing that its newly constructed 500-liter ADC-dedicated production facility will commence operations this February. Joseph Jeong, vice president of the ADC Development Team at Samsung Biologics, highlighted the rationale behind the expansion, emphasizing the company’s ability to leverage its established expertise in monoclonal antibody CDMO services to advance ADC therapeutics. "Samsung Biolog
Jan. 16, 2025
Hanmi Pharmaceutical steps up in global obesity drug race

SAN FRANCISCO ― Hanmi Pharmaceutical is poised to bring a new chapter to obesity treatment, a topic that has garnered significant attention at this year’s JP Morgan Healthcare Conference. Despite the spotlight on obesity drugs, industry concerns remain about potential side effects such as nausea, vomiting and overall muscle loss, which could lead to further complications for patients. Choi In-young, senior vice president and head of Hanmi Pharmaceutical's R&D Center, expressed confidence in the
Jan. 15, 2025
[JPM 2025] Samsung Biologics broadens biopharma horizons with new modality of investments

Samsung Group's biotech arm aims for major capacity boost, adding 720,000 liters through its second bio campus by 2032 SAN FRANCISCO-- Samsung Biologics CEO John Rim unveiled the company's strategy to ascend as a top-tier biopharmaceutical company, grounded in its "4E (Excellence)" approach, unveiled at the JP Morgan Healthcare Conference held in San Francisco, on Tuesday. The 4E framework encompasses the values that Samsung Biologics' employees embody: customer excellence, operational excellenc
Jan. 15, 2025
[JPM 2025] Celltrion highlights breakthrough therapies, unveils ambitious clinical plans by 2028

SAN FRANCISCO -- Celltrion unveiled a detailed road map for its innovative drug pipeline to global investors and expressed commitment to becoming a leading global player in innovative pharmaceuticals, expanding forward from a biosimilar-focused company. At the JP Morgan Healthcare Conference's main stage venue Tuesday, Celltrion CEO Seo Jin-seok delivered a presentation titled "Unveiling Strategy for Advancing Innovative Drug Pipelines," sharing its achievements in drug development and plans for
Jan. 14, 2025
Samsung Biologics secures largest-ever deal with European pharma giant

Samsung Group biotech unit is now Kospi's fourth-biggest company, outpacing world's largest CDMO, Lonza, in market cap Samsung Biologics has kicked off the start of 2025 with the largest single contract in the company's history, signing a record-breaking $1.41 billion deal, amounting to some 40 percent of the total orders received last year. On Tuesday, the company disclosed that it had signed a large-scale contract manufacturing organization agreement with a European pharmaceutical company. The
Jan. 12, 2025
Korean biotech leaders to take center stage at JP Morgan Healthcare Conference

A slew of Korean companies are set to showcase their latest developments from contract manufacturing to antibody drug conjugates pipelines at the 2025 JP Morgan Healthcare Conference, the world’s largest event in the pharmaceuticals and biotech industry, kicking off Monday in San Francisco. Now in its 43rd edition, the annual January gathering serves as a key platform for networking and collaboration, drawing industry experts and investors while offering insights into the latest trends and innov
Jan. 10, 2025
LG Chem expands into Thai beauty market with new skin booster

LG Chem announced Friday the launch of its new injectable skin booster, HP Vitaran, in Thailand, marking its latest move to strengthen its presence in Southeast Asia’s rapidly growing beauty market. HP Vitaran is formulated with polynucleotide, a regenerative, gel-like substance designed to improve skin texture and elasticity. Unlike topical skincare products, the treatment is injected directly into the skin, offering deeper, more visible and long-lasting results, the company said. The launch bu

1
2
3
4
5
6
7
8
9
10

EDITOR'S PICKS

Herald Corporation |CEO : Choi Jin-Young |Huam-ro 4-gil 10, Yongsan-gu, Seoul, Korea |Title : The Investor |Date of registration : 2016.06.21 |Date of issue : 2016.06.21
Publisher. Editor : Choi Jin-Young |Chief Privacy Officer & Juvenile Protection Manager : Choi He-suk |T +82-2-727-0021 |E investor@heraldcorp.com

FAMILY SITE GO

Company Registration No. 104-81-06004 |Mail-Order Business Registration 2016 - Seoul Yongsan - 00590 |Business info |Gov’t registration No. Seoul 아04099